Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Land & Improvements (2016 - 2023)

China Pharma Holdings filings provide 13 years of Land & Improvements readings, the most recent being $389808.0 for Q2 2023.

  • On a quarterly basis, Land & Improvements fell 7.12% to $389808.0 in Q2 2023 year-over-year; TTM through Jun 2023 was $389808.0, a 7.12% decrease, with the full-year FY2022 number at $404427.0, down 8.46% from a year prior.
  • Land & Improvements hit $389808.0 in Q2 2023 for China Pharma Holdings, down from $409895.0 in the prior quarter.
  • In the past five years, Land & Improvements ranged from a high of $443697.0 in Q1 2022 to a low of $389808.0 in Q2 2023.
  • Median Land & Improvements over the past 5 years was $413603.0 (2020), compared with a mean of $416443.1.
  • Biggest five-year swings in Land & Improvements: grew 9.59% in 2021 and later dropped 8.65% in 2022.
  • China Pharma Holdings' Land & Improvements stood at $403755.0 in 2019, then increased by 6.92% to $431681.0 in 2020, then rose by 2.34% to $441783.0 in 2021, then dropped by 8.46% to $404427.0 in 2022, then dropped by 3.61% to $389808.0 in 2023.
  • The last three reported values for Land & Improvements were $389808.0 (Q2 2023), $409895.0 (Q1 2023), and $404427.0 (Q4 2022) per Business Quant data.